# US 7,745,435 B2 · Triheterocyclic compounds and compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,435 B2
- Document ID: US7745435B2
- Status: Granted
- Kind: B2
- Application number: 12/176,123
- Filed: 2008-07-18
- Published: 2008-12-25
- Granted: 2010-06-29
- Earliest claimed: 2003-05-30
- Assignees: Gemix X Pharmaceuticals Canada Inc.
- Inventors: Giorgio Attardo; Jean-Francois Lavallee; Elise Rioux; Sasmita Tripathy; Terrence W. Doyle
- Web page: https://patentgrep.com/patent/US7745435B2

## Abstract

The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.

## Claims

### Claim 1

A compound of the Formula
or a pharmaceutically acceptable salt thereof wherein
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)OR14, —C(O)R14, —C(O)(CH2)n—R14, —O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R2 is —H, —C1-C8 alkyl or —OH;
R3 is —C1-C8 alkyl;
R4 is —Ym(Rb), wherein Rb is —H, halogen, —NH2, —CN, —NO2, —SH, —N3, —C1-C8 alkyl, —O—(C1-C8 alkyl), —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14,—O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —Ym—(Rc), wherein —Rc is —C1-C8 alkyl, —O—(C1-C8 alkyl), —O-benzyl, —NH2, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —CN, —NO2, —N3, —C2-C8 alkynyl, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R8 is —Ym(Rd), wherein —Rd is —H, —OH, halogen, amino, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —CN, —NO2, —N3, —C1-C8 alkyl, —(C1-C8 alkyl)-OH, —O—(C1-C8 alkyl), —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2), —R14,—O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R9 is —Ym(Re), wherein —Re is —H, —NH2, C1-C8 alkyl, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —C(O)N(C1-C5 alkyl)2, —NHC(O)(C1-C5 alkyl), —NHC(═NH2+)NH2, —CN, —NO2, N3, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14, —C(O)N(R14)2, —C(O)NHR14, -S-R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, —NR14C(S)N(R14)2;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —NH2, C1-C8 alkyl, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —C(O)NH(C1-C5 alkyl), —C(O)N(C1-C5 alkyl)2, —NHC(O)(C1-C5 alkyl), —NHC(═NH2+)NH2, —CN, —NO2, N3, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14, —O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, —NR14C(S)N(R14)2, with the proviso that neither R10 nor R12 is —OH;
each R14 is independently —H, —C1-C8 alkyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —C2-C8 alkenyl, or —C2-C8 alkynyl;
each Y is independently —C1-C8 alkylene-, —C2-C8 alkenylene- or —C2-C8 alkynylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 2 (depends on 1)

The compound of claim 1 where Q1 is —NH.

### Claim 3 (depends on 1)

The compound of claim 1 where Q1 is —NH—, Q4 is —CH—, and R2 is —H.

### Claim 4 (depends on 1)

The compound of claim 1 where Q1 is —NH—, Q4 is —CH—, and R2, R4, R8 and R10-R13 are —H.

### Claim 5 (depends on 1)

The compound of claim 1 where Q1 is —NH—, Q2 is —C(C1-C8 alkyl)-, Q3 is —C(C1-C8 alkyl)-, Q4 is —CH—, R7 is —O—(C1-C8 alkyl)-, and R2, R4, R8 and R10-R13 are —H.

### Claim 6

A composition comprising a pharmaceutically acceptable carrier or vehicle and an effective amount of a compound of the Formula
or a pharmaceutically acceptable salt thereof wherein
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C1-C8 alkyl, —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R2 is —H, —C1-C8 alkyl or —OH;
R3 is —C1-C8 alkyl;
R4 is —Ym(Rb), wherein Rb is —H, halogen, —NH2, —CN, —NO2, —SH, —N3, —C1-C8 alkyl, —O—(C1-C8 alkyl), —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14,—O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —Ym—(Rc), wherein —Rc is —C1-C8 alkyl, —O—(C1-C8 alkyl), —O-benzyl, —NH2, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —CN, —NO2, —N3, —C2-C8 alkynyl, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14,—O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R8 is —Ym(Rd), wherein —Rd is —H, —OH, halogen, amino, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —CN, —NO2, —N3, —C1-C8 alkyl, —(C1-C8 alkyl)-OH, —O—(C1-C8 alkyl), —C2-C8 alkenyl, —C2-C8 alkynyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2), —R14,—O—C(O)OR14, —O—C(O)NHR14, —O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, or —NR14C(S)N(R14)2;
R9 is —Ym(Re), wherein —Re is —H, —NH2, C1-C8 alkyl, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —C(O)N(C1-C5 alkyl)2, —NHC(O)(C1-C5 alkyl), —NHC(═NH2+)NH2, —CN, —NO2, N3, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —O—C(O)R14, —C(O)(CH2)n—R14,—O—C(O)OR14, —O—C(O)NHR14, —C(O)N(R14)2, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, —NR14C(S)N(R14)2;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —NH2, C1-C8 alkyl, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, —NH(phenyl), —N(phenyl)2, —NH(naphthyl), —N(naphthyl)2, —C(O)NH(C1-C5 alkyl), —C(O)N(C1-C5 alkyl)2, —NHC(O)(C1-C5 alkyl), —NHC(═NH2+)NH2, —CN, —NO2, N3, -3- to 9-membered heterocycle, —OR14, —O(CH2)nOR14, —C(O)R14, —O—C(O)R14, —C(O)(CH2)n—R14, —O—C(O)OR14, —O—C(O)NHR14,—O—C(O)N(R14)2, —C(O)N(R14)2, —C(O)OR14, —C(O)NHR14, —S—R14, —SOR14, —S(O)2R14, —NHC(O)R14, —NHSR14, —NHSOR14, —NHS(O)2R14, O—C(S)R14, O—C(S)OR14, O—C(S)NHR14, O—C(S)N(R14)2, —C(S)OR14, —C(S)NHR14, —C(S)N(R14)2, —NHC(S)R14, —NR14C(S)R14, —NHC(S)NHR14, —NHC(S)N(R14)2, —NR14C(S)NHR14, —NR14C(S)N(R14)2, with the proviso that neither R10 nor R12 is —OH;
each R14 is independently —H, —C1-C8 alkyl, —C3-C12 cycloalkyl, -phenyl , -naphthyl, -3- to 9-membered heterocycle, —C2-C8 alkenyl, or —C2-C8 alkynyl;
each Y is independently —C1-C8 alkylene-, —C2-C8 alkenylene- or —C2-C8 alkynylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 7 (depends on 1)

The compound of claim 1 where the pharmaceutically acceptable salt is tartrate salt or mesylate salt.

### Claim 8 (depends on 1)

The compound of claim 1 where the compound of Formula (Ia) is:
2-[5-4-iodo-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
5-bromo-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-3-(4-phenyl-piperazin-1-ylmethyl)-1H-indole;
2-({2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-3-hydroxymethyl-4-methoxy-5H-pyrrol-2-yl]-1H-indol-3-ylmethyl}-amino)-ethanol;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5-methoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-pyrrolidin-2-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-3-(2-pyrrolidin-2-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-4-yl ester;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propan-1-ol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-5-fluoro-1H-indole;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-6-fluoro-1H-indole;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-dimethylamino-phenyl)-amide;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-benzyloxy-phenyl)-amide;
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone;
4-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-ylmethyl}-phenol;
[2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-2H-pyrrol-3-yl]-(4-methoxy-phenyl)-amine;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid methyl ester; or
a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 6)

The composition of claim 6 where Q1 is —NH.

### Claim 10 (depends on 6)

The composition of claim 6 where Q1 is —NH—, Q4 is —CH—, and R2 is —H.

### Claim 11 (depends on 6)

The composition of claim 6 where Q1 is —NH—, Q4 is —CH—, and R2, R4, R8 and R10-R13 are —H.

### Claim 12 (depends on 6)

The composition of claim 6 where Q1 is —NH—, Q2 is —C(C1-C8 alkyl)-, Q3 is —C(C1-C8 alkyl)-, Q4 is —CH—, R7 is —O—(C1-C8 alkyl)-, and R2, R4, R8 and R10-R13 are —H.

### Claim 13 (depends on 6)

The composition of claim 6 where the pharmaceutically acceptable salt is tartrate salt or mesylate salt.

### Claim 14 (depends on 6)

The composition of claim 6 where the compound of Formula (Ia) is:
2-[5-4-iodo-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
5-bromo-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-3-(4-phenyl-piperazin-1-ylmethyl)-1H-indole;
2-({2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-3-hydroxymethyl-4-methoxy-5H-pyrrol-2-yl]-1H-indol-3-ylmethyl}-amino)-ethanol;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5-methoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-pyrrolidin-2-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-3-(2-pyrrolidin-2-yl-ethyl)-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-4-yl ester;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propan-1-ol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-5-fluoro-1H-indole;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-6-fluoro-1H-indole;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-dimethylamino-phenyl)-amide;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid(4-benzyloxy-phenyl)-amide;
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone;
4-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-ylmethyl}-phenol;
[2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-2H-pyrrol-3-yl]-(4-methoxy-phenyl)-amine;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid methyl ester; or
a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1 where
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C1-C8 alkyl, —C(O)R14, or —C(O)NHR14;
R2 is —H;
R3 is —C1-C8 alkyl;
R4 is —Ym(Rb), wherein Rb is —H, halogen, —OR14, or —C(O)OR14;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —Ym—(Rc), wherein —Rc is —O—(C1-C8 alkyl), —O-benzyl, —NH(phenyl), or —OR14;
R8 is —Ym(Rd), wherein —Rd is —H, or —OH;
R9 is —Ym(Re), wherein —Re is —H, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, or -3- to 9-membered heterocycle;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —OR14, or —O—C(O)OR14, or R11 and R12 together with the carbon atom to which each is attached, join to form a 5- to 9-membered heterocycle, with the proviso that neither R10 nor R12 is —OH;
each R14 is independently —H, —C1-C8 alkyl, -phenyl , or -3- to 9-membered heterocycle;
each Y is independently —C1-C8 alkylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 16 (depends on 15)

The compound of claim 15 where the compound is:
2-[5-4-iodo-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
5-bromo-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
{5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-2-[3-isopropylamino-methyl)-1H-indol-2-yl]-4-methoxy-5H-pyrrol-3-yl}-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5-methoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-4-yl ester;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propan-1-ol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-5-fluoro-1H-indole;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-6-fluoro-1H-indole;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-dimethylamino-phenyl)-amide;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-benzyloxy-phenyl)-amide;
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone;
4-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-ylmethyl}-phenol;
[2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-2H-pyrrol-3-yl]-(4-methoxy-phenyl)-amine; or
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid methyl ester; or
a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 6)

The composition of claim 6 where for the compound of Formula (Ia):
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C1-C8 alkyl, —C(O)R14, or —C(O)NHR14;
R2 is —H;
R3 is —C1-C8 alkyl;
R4 is —Ym(Rb), wherein Rb is —H, halogen, —OR14, or —C(O)OR14;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —Ym—(Rc), wherein —Rc is —O—(C1-C8 alkyl), —O-benzyl, —NH(phenyl), or —OR14;
R8 is —Ym(Rd), wherein —Rd is —H, or —OH;
R9 is —Ym(Re), wherein —Re is —H, —NH(C1-C5 alkyl), —N(C1-C5 alkyl)2, or -3- to 9-membered heterocycle;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —OR14, or —O—C(O)OR14, or R11 and R12 together with the carbon atom to which each is attached, join to form a 5- to 9-membered heterocycle, with the proviso that neither R10 nor R12 is —OH;
each R14 is independently —H, —C1-C8 alkyl, -phenyl , or -3- to 9-membered heterocycle;
each Y is independently —C1-C8 alkylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 18 (depends on 17)

The composition of claim 17 where the compound of Formula (Ia) is:
2-[5-4-iodo-3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
5-bromo-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indole;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
{5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-2-[3-isopropylamino-methyl)-1H-indol-2-yl]-4-methoxy-5H-pyrrol-3-yl}-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5-methoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
(2-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-ethoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-ethyl)-dimethyl-amine;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-3-(2-morpholin-4-yl-ethyl)-1H-indole;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-4-yl ester;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propan-1-ol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-5-fluoro-1H-indole;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-6-fluoro-1H-indole;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-dimethylamino-phenyl)-amide;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-benzyloxy-phenyl)-amide;
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone;
4-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-ylmethyl}-phenol;
[2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-2H-pyrrol-3-yl]-(4-methoxy-phenyl)-amine; or
3-{5-[5-(1H-indol-2-yl)-3-methoxy-pyrrol-2-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid methyl ester; or
a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The compound of claim 1 where
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C(O)R14, or —C(O)NHR14;
R2 is —H;
R3 is —C1-C8 alkyl;
R4 is —H;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —O—(C1-C8 alkyl), or —O-benzyl;
R8 is —Ym(Rd), wherein —Rd is —H, or —OH;
R9 is —Ym(Re), wherein —Re is —H, —NH(C1-C5 alkyl, or -3- to 9-membered heterocycle;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —OR14, or —O—C(O)OR14;
each R14 is independently —C1-C8 alkyl, or -phenyl ;
each Y is independently —C1-C8 alkylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 20 (depends on 19)

The compound of claim 19, where the compound is:
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-benzyloxy-phenyl)-amide; or
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone; or
a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 6)

The composition of claim 6, where for the compound of Formula (Ia):
Q1 is —N(R1)—;
Q2 is —C(R3)—;
Q3 is —C(R5)—;
Q4 is —C(R9)—;
R1 is —Ym(Ra), wherein —Ra is —H, —C(O)R14, or —C(O)NHR14;
R2 is —H;
R3 is —C1-C8 alkyl;
R4 is —H;
R5 is —C1-C8 alkyl;
R6 is —H;
R7 is —O—(C1-C8 alkyl), or —O-benzyl;
R8 is —Ym(Rd), wherein —Rd is —H, or —OH;
R9 is —Ym(Re), wherein —Re is —H, —NH(C1-C5 alkyl, or -3- to 9-membered heterocycle;
R10, R11, R12, and R13 are independently —Ym(Re), wherein —Re is —H, halogen, —OR14, or —O—C(O)OR14;
each R14 is independently —C1-C8 alkyl, or -phenyl ;
each Y is independently —C1-C8 alkylene-;
each m is independently 0 or 1; and
each n is independently an integer ranging from 0 to 6.

### Claim 22 (depends on 21)

The composition of claim 21, where the compound of Formula (Ia) is:
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene-4-methoxy-5H-pyrrol-2-yl]-3-morpholin-4-ylmethyl-1H-indole;
[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-2-(3-methylaminomethyl-1H-indol-2-yl)-5H-pyrrol-3-yl]-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
1-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-2-methyl-propan-1-one;
carbonic acid tert-butyl ester 2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indol-4-yl-ester;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-phenyl -methanone;
6-chloro-2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-isopropoxy-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-benzyloxy)-5H-pyrrol-2-yl]-1H-indole;
2-[5,(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid (4-benzyloxy-phenyl)-amide; or
(4-bromo-phenyl)-{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indol-1-yl}-methanone; or
a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

The compound of claim 1, wherein R3 and R5 are each —CH3.

### Claim 24 (depends on 6)

The composition of claim 6, wherein R3 and R5 of the compound of formula (Ia) are each —CH3.

### Claim 25 (depends on 15)

The compound of claim 15, wherein R3 and R5 are each —CH3.

### Claim 26 (depends on 19)

The compound of claim 19, wherein R3 and R5 are each —CH3.

### Claim 27

A compound being:
2-[4-methoxy-5-(3-methoxy-1H-pyrrol-2-ylmethylene)-5H-pyrrol-2-yl]-1H-indole;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5,6-dimethoxy-indole-1-carboxylic acid tert-butyl ester;
{5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-2-[3-isopropylamino-methyl)-1H-indol-2-yl]-4-methoxy-5H-pyrrol-3-yl}-methanol;
{2-[5-(3,5-dimethyl,-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}thiophen-3-yl-methanone;
[2-(3-allylaminomethyl-1H-indol-2-yl)-5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-3-yl]-methanol;
{2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-1H-indol-3-yl}-methanol;
2-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid 2,3-dihydroxy-propyl ester;
2-[5-[(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-indole-1-carboxylic acid tert-butyl ester;
(Z)-ethyl 2-(2-(2-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-3-methoxy-2H-pyrrol-5-yl)-1H-indol-3-yloxy)acetate; or
6-[5-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-4-methoxy-5H-pyrrol-2-yl]-5H-[1,3]dioxolo[4,5-f]indole, or
a pharmaceutically acceptable salt thereof.